Login / Signup

Drug survival of Adalimumab biosimilar vs Adalimumab originator in Hidradenitis Suppurativa: can equivalence be assumed? A retrospective cohort study.

Mercè Grau-PerezLaura Rodríguez-AguilarGaston RoustanFernando Alfageme
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Keyphrases
  • hidradenitis suppurativa
  • adverse drug
  • emergency department